|
Peer support for diabetes, heart disease and HIV/AIDS: a review of the clinical effectiveness, cost-effectiveness, and guidelines |
CADTH |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Peer support for diabetes, heart disease and HIV/AIDS: a review of the clinical effectiveness, cost-effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions Peer support may provide some benefits to patients with chronic diseases such as type 2 diabetes, heart disease and HIV/AIDS, but the findings are inconsistent and evidence is limited. In patients with type 2 diabetes, peer support was shown to improve clinical, health behavioural, empowerment, and psychological outcomes. Peer support was also shown to reduce pain, anxiety, emergency room visits and increase self-efficacy, condition knowledge in patients with heart disease. In patients with HIV/AIDS, peer support may favourably affect sexual risk behavior, attitudes and cognition, HIV knowledge and substance use. Results from a cost-effectiveness analysis of peer support suggest that the intervention may be cost-effective in patients with diabetes, and there was no statistically significant difference in total health care cost between peer support and usual care. Peer support is recommended as a good practice to increase treatment adherence for patients with HIV/AIDS but because of lack of strong supportive evidence, the recommendation is only on the basis of individual patient circumstances. Indexing Status Subject indexing assigned by CRD MeSH Cardiovascular Diseases; Diabetes Mellitus; Education, Nonprofessionals; HIV Infections; Peer Group; Social Support Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000891 Date abstract record published 17/07/2014 |
|
|
|